🇺🇸 FDA
Pipeline program

GPRC5D CAR-T cell intravenous infusion

XBAP2025-9

Phase 1 mab active

Quick answer

GPRC5D CAR-T cell intravenous infusion for Plasma Cell Dyscrasias is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Plasma Cell Dyscrasias
Phase
Phase 1
Modality
mab
Status
active

Clinical trials